Abrar Qureshi, MD
Dermatology · Providence, RINPI 1720044134
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,434 of the $38,312 with a category attached, or 87.3%. 15 manufacturers reported payments, led by Incyte Corporation at 58.2% of the total. Reporting peaked in 2024 at $20,398 and has fallen 56.2% since, to $8,926 in 2025. Among dermatology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $430.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$22K
- UCB, Inc.$10K
- Galderma Laboratories, L.p.$5K
- LEO Pharma Inc.$390
- AbbVie$222
- Johnson & Johnson$147
- plus $417 from 9 others
Across 56 payments — averaging $16,110 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$477K
- UCB SA$223K
- Regeneron$113K
- Astrazeneca UK Limited$50K
- AbbVie$29K
- Novartis$5K
- plus $5K from 2 others
What the payments were for
- Consulting fees$33,43487%
- Travel & lodging$2,4866%
- Food & beverage$2,3936%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 32 | $22,286 |
| UCB, Inc. | 16 | $9,729 |
| Galderma Laboratories, L.p. | 1 | $5,122 |
| LEO Pharma Inc. | 16 | $390 |
| AbbVie | 12 | $222 |
| Johnson & Johnson | 1 | $147 |
| Lilly USA, LLC | 1 | $124 |
| Novartis | 1 | $81 |
| Sun Pharmaceutical Industries Inc. | 1 | $75 |
| Boehringer Ingelheim | 3 | $40 |
| E.r. Squibb & Sons, L.L.C. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Dermavant Sciences, Inc. | 1 | $15 |
| Sanofi | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,312 in reported general payments places this provider in the 90th percentile of 61 dermatology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 23 | $281,757 |
| RinvoqUpadacitinib | 30 | $198,894 |
| Cimzia (2 Pack)Certolizumab Pegol | 12 | $128,337 |
| Taltz AutoinjectorIxekizumab | 11 | $112,261 |
| OtezlaApremilast | 17 | $87,569 |
| Humira PenAdalimumab | 13 | $84,539 |
| Dupixent SyringeDupilumab | 18 | $76,597 |
| Fluorouracil | 38 | $2,821 |
| Acitretin | 13 | $2,537 |
| Hydroxychloroquine Sulfate | 53 | $1,673 |
| MethotrexateMethotrexate Sodium | 69 | $1,613 |
| Azathioprine | 23 | $1,348 |
| Tacrolimus | 11 | $835 |
| Metronidazole | 14 | $773 |
| Mycophenolate Mofetil | 11 | $696 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $222 | $198,89430 claims |
| UCB, Inc.Cimzia (2 Pack) | $9,729 | $128,33712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 61 dermatology providers in Rhode Island.
Other dermatology in Providence
- Helena KuhnProvidence$63K
- Martin WeinstockProvidence$62K
- Farah MoustafaProvidence$51K
- Scott HammermanProvidence$9K
- Laura della TorreProvidence$9K
- Benjamin KahnProvidence$4K
- Rachel HoffmannProvidence$4K
- Jennie MugliaProvidence$2K
- Daniella ReimannProvidence$2K
- Gladys TelangProvidence$624
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.